Mayne Pharma Group Limited (MAYNF)
| Market Cap | 182.13M -35.1% |
| Revenue (ttm) | 265.43M -6.0% |
| Net Income | 16.93M |
| EPS | 0.14 |
| Shares Out | n/a |
| PE Ratio | 10.76 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,000 |
| Open | 2.370 |
| Previous Close | 2.370 |
| Day's Range | 2.350 - 2.370 |
| 52-Week Range | 1.400 - 4.000 |
| Beta | 1.00 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and in... [Read more]
News
Mayne Pharma Group Earnings Call Transcript: H2 2026
FY 2026 saw revenue decline 6% to AUD 383.7 million due to FX, but gross margin rose to 64.7%. DistributeRx exceeded expectations, and women's health and dermatology segments showed resilience despite headwinds. FY 2027 outlook is positive, with margin improvement and growth initiatives underway.
Mayne Pharma Group Annual report: H2 2026
Mayne Pharma Group has published its H2 2026 annual report on August 26, 2026.
Mayne Pharma Group Earnings release: H2 2026
Mayne Pharma Group released its H2 2026 earnings on August 26, 2026, summarizing the period's financial results.
Mayne Pharma Group Slides: H2 2026
Mayne Pharma Group has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 26, 2026.
Mayne Pharma investors push for break-up after blocked takeover bid
Investors in the Adelaide-based company are not ruling out seeking a board spill if management fails to take drastic action to increase shareholder value.
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
Mayne Pharma Group Slides: Investor presentation
Mayne Pharma Group has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Mayne Pharma Group Transcript: ASX Small Caps Conference 2026
After a failed takeover and significant share price drop, the company has shifted to branded pharma, launched DistributeRx™ to streamline U.S. distribution, and is focused on growing Women's Health and Dermatology. Key growth drivers include new distribution models and increased menopause therapy adoption.
Mayne Pharma Group Transcript: Investor update
DistributeRx's launch marks a strategic shift to direct-to-patient pharmaceutical distribution, reducing intermediaries and improving profitability. The model leverages existing infrastructure, delivers transparent pricing, and is highly scalable, with strong early adoption in dermatology and significant growth potential as the U.S. cash pay market expands.
Mayne Pharma Group Press release: Investor update
Mayne Pharma Group issued a press release on March 10, 2026, disclosing material business information to investors.
Mayne Pharma Group Slides: Investor update
Mayne Pharma Group has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Mayne Pharma Group Earnings Call Transcript: H1 2026
Revenue was flat at AUD 212.1m, but gross margin rose to 65.3% and underlying EBITDA was AUD 28.6m, down 8%. Dermatology drove margin gains, while women's health saw strong demand but higher investment. Leadership transition and legal actions mark significant developments.
Mayne Pharma Group Quarterly report: H1 2026
Mayne Pharma Group has published its H1 2026 quarterly earnings report on February 22, 2026.
Mayne Pharma Group Slides: H1 2026
Mayne Pharma Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 22, 2026.
Mayne Pharma Group Earnings release: H1 2026
Mayne Pharma Group released its H1 2026 earnings on February 22, 2026, summarizing the period's financial results.
Mayne Pharma Group Transcript: AGM 2026
The AGM highlighted strong FY 2025 financial results, strategic focus on branded products, and Board changes. Shareholders raised concerns on royalties, dividends, and the failed Cosette takeover. All resolutions were put to poll, with no proxy advisor opposition.
Mayne Pharma Group Slides: FY 2026
Mayne Pharma Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on January 28, 2026.
Termination of Proposed Acquisition of Mayne Pharma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma ...
Australia Blocks U.S.-Based Cosette's $387.2 Million Takeover of Mayne Pharma
Australia's government said it would block a $387.2 million takeover of Mayne Pharma by U.S. company Cosette Pharmaceuticals on national security grounds, citing a need to protect critical medical sup...
Australia blocks Cosette Pharmaceuticals bid to buy Mayne Pharma
Australia on Friday blocked a A$672 million ($433 million) buyout offer for Mayne Pharma from U.S. drugmaker Cosette Pharmaceuticals, citing national interest.
Australia's Mayne Pharma falls as treasurer considers blocking Cosette's $437 million bid
Australia's Mayne Pharma said on Friday it had received a letter from its potential acquirer, Cosette, indicating that the country's treasurer is considering blocking the A$672 million ($436.67 millio...
Cosette's attempt to drop $438 million Mayne Pharma deal denied by court
An Australian court has moved to prevent U.S. drugmaker Cosette Pharmaceuticals from abandoning its A$672 million ($437.6 million) acquisition of Mayne Pharma , the ASX-listed company said on Thursday...
Mayne Pharma Group Earnings Call Transcript: H2 2025
FY25 saw 5% revenue growth to $408.1 million, with gross margin up to 60.6% and EBITDA more than doubling. Women's health led growth, while dermatology faced generic competition but improved margins. The Cosette acquisition scheme received strong shareholder support.
Mayne Pharma Group Annual report: H2 2025
Mayne Pharma Group has published its H2 2025 annual report on August 28, 2025.
Mayne Pharma Group Slides: H2 2025
Mayne Pharma Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 28, 2025.